Annual Review of Cancer Biology

Papers
(The median citation count of Annual Review of Cancer Biology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma?114
Regulatory T Cells in Cancer78
Lactate and Acidity in the Cancer Microenvironment63
Metabolism in the Tumor Microenvironment61
RNA Modifications in Cancer: Functions, Mechanisms, and Therapeutic Implications58
Mitophagy and Mitochondrial Dysfunction in Cancer43
The Pleiotropic Role of the KEAP1/NRF2 Pathway in Cancer42
The Epithelial-to-Mesenchymal Transition in Development and Cancer42
Targeting MYC Proteins for Tumor Therapy40
Investigating Tumor Heterogeneity in Mouse Models39
The Role of Translation Control in Tumorigenesis and Its Therapeutic Implications37
WNT and β-Catenin in Cancer: Genes and Therapy36
Reactivation of Endogenous Retroelements in Cancer Development and Therapy35
Metabolic Drivers in Hereditary Cancer Syndromes30
Biomarkers for Response to Immune Checkpoint Blockade28
The Bidirectional Relationship Between Cancer Epigenetics and Metabolism27
Immunometabolism in the Tumor Microenvironment27
Small-Molecule Approaches to Targeted Protein Degradation27
Telomeres and Cancer: Resolving the Paradox26
Toward Targeting Antiapoptotic MCL-1 for Cancer Therapy25
Cancer-Associated Cachexia: A Systemic Consequence of Cancer Progression25
Humanized Mouse Models to Evaluate Cancer Immunotherapeutics24
Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy21
The Multifaceted Role of Regulatory T Cells in Breast Cancer21
AMP-Activated Protein Kinase: Friend or Foe in Cancer?20
Reinventing Radiobiology in the Light of FLASH Radiotherapy20
Nongenetic Mechanisms of Drug Resistance in Melanoma17
Myeloid-Derived Suppressor Cells: Facilitators of Cancer and Obesity-Induced Cancer15
Central Role of the Antigen-Presentation and Interferon-γ Pathways in Resistance to Immune Checkpoint Blockade15
Reeling in the Zebrafish Cancer Models14
Targeting KRAS G12C with Covalent Inhibitors13
Molecular Heterogeneity and Evolution in Breast Cancer13
Cancer Immunotherapy and the Nectin Family13
Engineering T Cells to Treat Cancer: The Convergence of Immuno-Oncology and Synthetic Biology13
The Neural Regulation of Cancer12
Nutritional Preconditioning in Cancer Treatment in Relation to DNA Damage and Aging12
Acquired Resistance in Lung Cancer12
Personal Neoantigen Vaccines for the Treatment of Cancer12
Targeting BET Bromodomains in Cancer10
Deregulation of Chromosome Segregation and Cancer10
Novel Mouse Models for Cancer Immunology9
Cancer Genomic Rearrangements and Copy Number Alterations from Errors in Cell Division9
The Role of Phase-Separated Condensates in Fusion Oncoprotein–Driven Cancers9
Ex Vivo Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics9
Strategies for Heating Up Cold Tumors to Boost Immunotherapies8
Cancer Dependencies: PRMT5 and MAT2A in MTAP/p16-Deleted Cancers8
Single-Cell Epigenomics Reveals Mechanisms of Cancer Progression8
Development of Tissue-Agnostic Treatments for Patients with Cancer7
TGFβ: Signaling Blockade for Cancer Immunotherapy7
Immune-Based Approaches for the Treatment of Pediatric Malignancies7
Oncohistones: Hijacking the Histone Code7
0.01708197593689